Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2003

View Archived Issues

Roxifiban does not activate platelets from healthy volunteers

Pozen submits MT-100 NDA

Medivir licenses MIV-150 to Population Council

Kyorin and Eisai amend Maxalt agreement

MOR-201 program discontinued in Q2 at MorphoSys

Oxagen identifies novel diabetes gene

FDA approval for Rebetol in pediatric hepatitis C

Probactrix controls HIV-associated diarrhea in clinical trial

Health Canada grants clearance for initiation of phase II studies of Infecton

Pfizer returns P-57 rights to Phytopharm

Strategic review and Q2 results at Shire

Combination therapies for allergic diseases comprising an anti-IgE antibody and antiallergic agent

Use of amylin agonists for reducing triglyceride levels

Adenosine receptor ligands and their use in depression and other disorders

IGF-I peptides useful in ophthalmology and dermatology

Bristol-Myers Squibb presents new antiviral compounds

New nuclear hormone receptor modulators synthesized at BMS

Camptothecin encapsulated in cationic liposomes targets tumor blood vessels

LipoRed: a cationic liposome-based neovascular imaging agent

AVE-8062A: a tumor vasculature targeting agent with promising antitumor activity

Additional mechanism of action for IGN-311: inhibition of growth factor signaling

Prous Science announces the addition of Chronic Rhinosinusitis to the Drug R&D Backgrounders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...